Sajad Khiali
Overview
Explore the profile of Sajad Khiali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Namdar H, Khani E, Khiali S, Safaie N, Ameli H, Rahbari Banaeian G, et al.
J Cardiovasc Thorac Res
. 2024 Apr;
16(1):49-54.
PMID: 38584664
Introduction: Since there is a bi-directional interaction between hypertension and depression, we aimed to evaluate the effects of citalopram administration in the management of hypertension. Methods: A randomized clinical trial...
2.
Khiali S, Taban-Sadeghi M, Sarbakhsh P, Khezerlouy-Aghdam N, Entezari-Maleki T
Eur J Clin Pharmacol
. 2023 Dec;
80(2):301-303.
PMID: 38040994
No abstract available.
3.
Khiali S, Taban-Sadeghi M, Sarbakhsh P, Khezerlouy-Aghdam N, Entezari-Maleki T
Eur J Clin Pharmacol
. 2023 Oct;
80(1):93-104.
PMID: 37897527
Purpose: There is accumulating evidence regarding the potential benefits of empagliflozin in individuals with acute myocardial infarction (MI). Based on the literature, colchicine could also reduce the risk of MI...
4.
Khiali S, Taban-Sadeghi M, Sarbakhsh P, Khezerlouy-Aghdam N, Namdar H, Salehi R, et al.
Trials
. 2023 Oct;
24(1):645.
PMID: 37803449
Background: Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on...
5.
Khiali S, Taban-Sadeghi M, Sarbakhsh P, Khezerlouy-Aghdam N, Rezagholizadeh A, Asham H, et al.
J Clin Pharmacol
. 2023 Jul;
63(12):1307-1323.
PMID: 37455561
Despite the growing body of evidence regarding the beneficial cardiovascular effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, clinical data in individuals without diabetes, heart failure (HF), and/or chronic kidney disease (CKD)...
6.
Khiali S, Agabalazadeh A, Sahrai H, Baghi H, Rahbari Banaeian G, Entezari-Maleki T
Pharmaceut Med
. 2023 Mar;
37(2):139-151.
PMID: 36995515
The incidence of cardiovascular diseases has significantly increased with the expansion of the industrialization of societies, which is notably linked to lifestyle changes and an unhealthy diet. Hence, determining the...
7.
Khiali S, Rezagholizadeh A, Behzad H, Baghi H, Entezari-Maleki T
Postgrad Med
. 2022 Dec;
135(2):102-120.
PMID: 36567602
Currently, the world is recovering from the shock of the coronavirus disease 2019 (COVID-19) pandemic; however, this situation is still fragile. Health authorities recommend administering COVID-19 vaccines as the safest...
8.
Khiali S, Rezagholizadeh A, Entezari-Maleki T
Bioimpacts
. 2022 Jun;
12(3):291-292.
PMID: 35677665
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis with a growing number of mortalities and morbidities worldwide. Despite performing numerous researches, there are...
9.
Khiali S, Entezari-Maleki T
J Clin Pharmacol
. 2022 May;
62(9):1055-1058.
PMID: 35522372
No abstract available.
10.
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
Khiali S, Khani E, B Rouy S, Entezari-Maleki T
Future Microbiol
. 2022 Feb;
17:377-391.
PMID: 35199608
Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19...